| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the University of Medicine & Dentistry of New Jersey (Dr. Sachdeo), New Brunswick; University of Michigan Medical Center (Dr. Beydoun), Ann Arbor; Beth Israel Deaconess Medical Center Comprehensive Epilepsy Program and Department of Neurology (Dr. Schachter), Harvard Medical School, Boston, MA; Comprehensive Epilepsy Center (Dr. Vasquez), New York University Hospital–Cornell Medical Center, New York, NY; Long Island Jewish Medical Center (Dr. Schaul), New Hyde Park, NY; and Novartis Pharmaceuticals Corporation (Drs. Mesenbrink, Kramer, and D’Souza), East Hanover, NJ.
Address correspondence and reprint requests to Dr. R. Sachdeo, University of Medicine & Dentistry of New Jersey, New Jersey Comprehensive Epilepsy Center, 97 Paterson Street, New Brunswick, NJ; e-mail:sachderc{at}umdnj.edu
Objective: — To evaluate the efficacy and safety of oxcarbazepine (OXC) as monotherapy for patients with uncontrolled partial seizures.
Methods: — A multicenter, double-blind, randomized, parallel-group, dose-controlled monotherapy trial compared OXC at 2400 mg/day with OXC at 300 mg/day in patients with uncontrolled partial-onset seizures previously receiving carbamazepine (CBZ) monotherapy. During a 28-day open-label conversion phase, patients were tapered off CBZ and titrated to OXC 2400 mg/day. After a 56-day open-label baseline phase on OXC 2400 mg/day, patients entered a 126-day double-blind treatment phase in which they were randomized to continue OXC at 2400 mg/day or were down titrated over 6 weeks to OXC at 300 mg/day. Patients met the efficacy endpoint by completing the double-blind treatment phase or by meeting one of four predefined exit criteria. The primary efficacy variable was time to meeting one of the exit criteria. The secondary efficacy variable was the percentage of patients meeting one of the exit criteria in each of the two treatment groups.
Results: — Of the 143 patients enrolled, 96 were randomized in the double-blind treatment phase. Time to meeting an exit criterion was significantly in favor of the OXC 2400 mg/day group (p = 0.0001). The median time to meeting an exit criterion was 68 days for the OXC 2400 mg/day Group and 28 days for the OXC 300 mg/day Group. In addition, the percentage of patients meeting one of the exit criteria was significantly lower for the OXC 2400 mg/day Group (p = 0.0001). Overall, OXC was well tolerated with the most common adverse events consisting of fatigue, nausea, ataxia, and headache.
Conclusion: — This trial demonstrated that OXC at 2400 mg/day is well tolerated and efficacious when administered as monotherapy in patients with uncontrolled partial onset seizures.
This article has been cited by other articles:
|
|
 |
|
  S. Silberstein, J. Saper, F. Berenson, M. Somogyi, K. McCague, and J. D'Souza Oxcarbazepine in migraine headache: A double-blind, randomized, placebo-controlled study Neurology, February 12, 2008; 70(7): 548 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sachdeo Monotherapy clinical trial design Neurology, December 11, 2007; 69(24_suppl_3): S23 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Glauser, D. J. Dlugos, W. E. Dodson, A. Grinspan, S. Wang, S.-C. Wu, and and the EPMN-106/INT-28 Investigators Topiramate Monotherapy in Newly Diagnosed Epilepsy in Children and Adolescents J Child Neurol, June 1, 2007; 22(6): 693 - 699. [Abstract] [PDF]
|
|
|
|
|
|
N. Katz Methodological issues in clinical trials of opioids for chronic pain Neurology, December 29, 2005; 65(12_suppl_4): S32 - S49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shinnar and J. M. Pellock The trials and tribulations of pediatric drug trials Neurology, November 8, 2005; 65(9): 1348 - 1349. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Pina-Garza, R. Espinoza, D. Nordli, D. A. Bennett, S. Spirito, T. E. Stites, D. Tang, and Y. Sturm Oxcarbazepine adjunctive therapy in infants and young children with partial seizures Neurology, November 8, 2005; 65(9): 1370 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology, April 27, 2004; 62(8): 1261 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. LaRoche and S. L. Helmers The New Antiepileptic Drugs: Scientific Review JAMA, February 4, 2004; 291(5): 605 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Beydoun and E. Kutluay Conversion to monotherapy: Clinical trials in patients with refractory partial seizures Neurology, June 10, 2003; 60(90114): S13 - 25. [Abstract] [Full Text]
|
|
|
|
 |
|
 {blacktriangledown}Oxcarbazepine for epilepsy - a useful new choice? DTB, June 1, 2002; 40(6): 46 - 48. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
